Pattern of autologous stem cell transplants at a tertiary care government hospital, with emphasis on transplant outcomes with pre-harvest CD34+ level

• Published in: Blood cell therapy 2022-02, Vol.5 (1), p.16-26
• Main Authors: Dolai, Tuphan Kanti, De, Rajib, Sen, Ankita, Baul, Shuvra Neel, Mitra, Sumit, Bhattacharya, Subham, Mondal, Indrani, Mukhopadhyay, Kaushik, Chattopadhyay, Arnab, Dutta, Shyamali, Mandal, Prakas Kumar
• Format: Article
• Language: English
• ISSN: 2432-7026; 2432-7026
• DOI: 10.31547/bct-2021-010

Autologous stem cell transplantation (ASCT) is an established therapy for many hematological diseases. This study assessed the pattern of ASCTs at a tertiary care center and associated factors, including pre-harvest CD34+ stem cell levels, leading to improved engraftment outcomes. A retrospective study was conducted in India, between February 2009-August 2020. Patients who underwent ASCT for different hematological malignancies (n=65) were included, and the patients' age, sex, type and stage of disease, pre- and post-harvest CD34+ counts, and time to attain platelet/neutrophil engraftment or febrile neutropenia were analyzed. The post-harvest CD34+ dose was calculated. Pre-conditioning was performed using Granulocyte Colony Stimulating Factor (GCSF)±Plerixafor. Progression-free survival (PFS) was calculated using relapse/death as the endpoint. The median age of the cohort (n=65) was 49 years, with a male preponderance. Multiple myeloma was the most common malignancy (70.8% [46/65]), requiring ASCT. The median time to ASCT was 13 months. All patients had received GCSF, while Plerixafor was used in 17 patients with a pre-harvest CD34+ count of